Chain of Compliance™ is vital for the Regenerative Medicine Advanced Therapy (RMAT) market which presents a major opportunity for the industry. In a recent Contract Pharma article, Mark W. Sawicki, Ph.D., Chief Commercial officer of Cryoport, discusses why the Chain of Compliance™ is critical to winning in the RMAT market. Read more >
